444606-18-2 Usage
Uses
Used in Sleep Disorder Treatment:
SB-681323 is used as a therapeutic agent for treating sleep disorders, leveraging its ability to regulate the circadian clock and potentially improve sleep patterns.
Used in Cancer Therapy:
SB-681323 is used as an anticancer agent, particularly for certain types of cancer. Its mechanism of action involves modulating the cell cycle progression, which can help in controlling tumor growth and potentially enhancing the efficacy of conventional cancer treatments.
Used in Neurodegenerative Disease Management:
SB-681323 is used as a therapeutic intervention for neurodegenerative diseases, where its modulation of the phosphorylation of target proteins may help in slowing down or managing the progression of these diseases.
Used in Drug Development:
SB-681323 is used as a lead compound in drug development, given its specificity for CK1δ and its demonstrated potential in various medical conditions. Further research is ongoing to explore its full therapeutic potential and optimize its use in clinical settings.
Check Digit Verification of cas no
The CAS Registry Mumber 444606-18-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,4,6,0 and 6 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 444606-18:
(8*4)+(7*4)+(6*4)+(5*6)+(4*0)+(3*6)+(2*1)+(1*8)=142
142 % 10 = 2
So 444606-18-2 is a valid CAS Registry Number.
444606-18-2Relevant articles and documents
NOVEL PROCESS AND FORMULATIONS
-
Page/Page column 87-88, (2010/11/27)
The present invention provides for a novel process of making 6-carboxylic acid derivatives of pyrido[2,3-d]pyrimidin-7-one's, as well as a novel process for making 8-(2,6-difluorophenyl)-4-(4-fluoro-2-methylphenyl)-2-{[2-hydroxy-l- (hydroxymethyl)ethyl]-amino}pyrido[2,3-d]pyrimidin-7(8H)-one, and salts thereof.
Novel compounds
-
Page 37-38, (2008/06/13)
Novel substituted 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy as CSBP/p38 kinase inhibitors.
